Pharmaceuticals group
Sinclair Pharma said it expects to achieve profitability this year despite a decline in product sales due to de-stocking by wholesalers. Revenues this year have been underpinned by licensing and royalty payments and an increase in new sales and marketing agreements, the group said in a statement. Sinclair launched two new products this year: Sebclair Cream for seborrhoeic dermatitis in Spain and Jonctum for stretch marks in France. It launched a string of new products with partners.Specialist healthcare group Ark Therapeutics is up after it said it remains well-funded to make continued progress in its lead clinical and pre-clinical programmes. "Ark has made good progress in building its business. This is particularly evident with our gene-based products where we are pioneering breakthrough biomedicines for areas of high unmet medical need," said chief executive Nigel Parker."It is clear that Ark has strengthened its product portfolio as well as its unique manufacturing asset. We remain very focused on using our resources in a way which will enable us to deliver shareholder value," he added.FTSE TechMARK - FallersCorin Group (CRG) 49.00p -5.77%Puricore (PURI) 11.50p -4.17%Sinclair Pharma (SPH) 29.00p -4.13%Oxford Instruments (OXIG) 140.00p -4.11%BATM Advanced (BVC) 32.25p -3.01%Alphameric (ALM) 25.25p -2.88%Psion (PON) 60.25p -2.03%ProStrakan (PSK) 79.75p -1.85%Microgen (MCGN) 55.00p -1.79%Intec Telecom (ITL) 42.25p -1.74%FTSE TechMARK - RisersTorotrak (TRK) 34.00p +11.48%Alizyme (AZM) 7.50p +11.11%Sepura (SEPU) 54.00p +9.64%Ark Therapeutics (AKT) 53.25p +6.50%Vernalis (VER) 4.15p +5.06%Total Systems (TTS) 31.50p +3.28%Skyepharma (SKP) 175.00p +2.64%Robotic Technology (RTS) 5.00p +2.56%Filtronic (FTC) 31.25p +2.46%Optos (OPTS) 43.50p +2.35%